Quantitative Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Quantitative Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-138,583	Closed	-$378K	–	458
2025 Q4	$378K	Buy	+138,583	New	+$321K	0.04%	341
2024 Q3	–	Sell	-187,508	Closed	-$1.5M	–	380
2024 Q2	$1.5M	Buy	+187,508	New	+$2.01M	0.16%	120
2021 Q4	–	Sell	-11,442	Closed	-$282K	–	353
2021 Q3	$282K	Buy	+11,442	New	+$270K	0.03%	334
2016 Q4	–	Sell	-14,100	Closed	-$116K	–	864
2016 Q3	$116K	Sell	14,100 -400	-3%	-$3.38K	﹤0.01%	644
2016 Q2	$117K	Buy	+14,500	New	+$91.1K	0.01%	697

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Quantitative Investment Management's IOVA Position: Q1 2026 in Review

Quantitative Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 138,583 shares — an estimated $378K sold.

Quantitative Investment Management first reported a position in IOVA in Q2 2016 and held it in 5 quarters. The position peaked at $1.5M in Q2 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Quantitative Investment Management reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Quantitative Investment Management sold 138,583 Iovance Biotherapeutics shares in Q1 2026, an estimated $378K.
Quantitative Investment Management first reported a position in Iovance Biotherapeutics in Q2 2016 and held it in 5 quarters.
Quantitative Investment Management's Iovance Biotherapeutics position peaked at $1.5M in Q2 2024.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Quantitative Investment Management's 13F filing for Q1 2026, filed 15 May 2026.